JBT Marel (JBTM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
1 Apr, 2026Voting matters and shareholder proposals
Election of ten directors is proposed, with individual nominees listed for shareholder approval at the annual meeting on May 14, 2026.
Advisory vote on executive compensation (say-on-pay) is included as a non-binding resolution.
Ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2026 is up for shareholder vote.
Shareholders may address other matters that properly come before the meeting or any adjournment.
Board of directors and corporate governance
Board recommends voting in favor of all director nominees and proposals presented.
Director nominees include a mix of current and potentially new members, reflecting board continuity and diversity.
Executive compensation and say-on-pay
Advisory vote seeks shareholder approval of named executive officers' compensation, providing input on pay practices.
Latest events from JBT Marel
- Q2 2026 saw 5% revenue growth, strong orders, and improved margins, with guidance reaffirmed.JBTM
Q2 2026 - $3.9B TTM revenue, 16.2% EBITDA margin, and strong recurring revenue drive growth and resilience.JBTM
Investor presentation - All director nominees and proposals were approved, with no questions from stockholders.JBTM
AGM 2026 - Q1 2026 saw 10% revenue growth, $45M net income, and strong Protein Solutions margin gains.JBTM
Q1 2026 - Proxy details director elections, pay-for-performance, and strong ESG focus after a transformative merger.JBTM
Proxy filing - Targeting 5–7% organic growth and >20% EBITDA margin by 2028 through digital integration.JBTM
Investor Day 2026 - 2025 saw record revenue and synergy gains, with 2026 set for further growth and margin expansion.JBTM
Q4 2025 - Merger creates a global food tech leader with strong synergies, closing by year end 2024.JBTM
Business Combination - Q1 2025 revenue hit $854M, but one-time charges drove a $173M net loss; outlook cautious.JBTM
Q1 2025